Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas

Journal of Clinical Oncology

Volumn 18, Issue 3, 2000, Pages 636-645

  Smith, Justin S ^a   Perry, Arie ^a   Borell, Thomas J ^a   Lee, Hyun K ^a   O'Fallon, Judith ^a   Hosek, Sandra M ^a   Kimmel, David ^a   Yates, Allan ^a   Burger, Peter C ^a   Scheithauer, Bernd W ^a   Jenkins, Robert B ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CARMUSTINE; CYCLOPHOSPHAMIDE; ETOPOSIDE; LOMUSTINE; PROCARBAZINE; VINCRISTINE;

ADULT; AGED; ARTICLE; ASTROCYTOMA; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CHROMOSOME 19Q; CHROMOSOME 1P; CHROMOSOME MAP; CONTROLLED STUDY; DRUG SENSITIVITY; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; OLIGODENDROGLIOMA; PHENOTYPE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS;

EID: 0033951824     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.2000.18.3.636     Document Type: Article

References (40)

1. Kleihues P, Burger PC, Scheithauer BW: Histological Typing of Tumours of the Central Nervous System. Berlin, Germany, Springer-Verlag, 1992
2. Lopes MBS, VandenBerg SR, Scheithauer BW: The World Health Organization classification of nervous system tumors in experimental neuro-oncology, in Levin AJ, Schmidek HH (eds): Molecular Genetics of Nervous System Tumors. New York, NY, Wiley-Liss, 1993, pp 1-36
3. Smith JS, Alderete B, Minn Y, et al: Localization of common deletion regions on 1p and 19q in human gliomas and their association with histological subtype. Oncogene 18:4144-4152, 1999
4. Rorke LB: Pathologic diagnosis as the gold standard. Cancer 7:665-667, 1997 (editorial)
5. Cairncross JG, Macdonald DR: Successful chemotherapy for recurrent malignant oligodendroglioma. Ann Neurol 23:350-364, 1988
6. Glass J, Hochberg FH, Gruber ML, et al: The treatment of oligodendrogliomas and mixed oligodendroglioma-astrocytomas with PCV chemotherapy. J Neurosurg 76:741-745, 1992
7. Cairncross G, Macdonald D, Ludwin S, et al: Chemotherapy for anaplastic oligodendroglioma. J Clin Oncol 12:2013-2021, 1994
8. Kim L, Hochberg FH, Thornton AF, et al: Procarbazine, lomustine, and vincristine (PCV) chemotherapy for grade III and grade IV oligoastrocytomas. J Neurosurg 85:602-607, 1996
9. Mason WP, Krol GS, DeAngelis LM: Low-grade oligodendroglioma responds to chemotherapy. Neurology 46:203-207, 1996
10. Cairncross JG, Ueki K, Zlatescu C, et al: Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendroglioma. J Natl Cancer Inst 90:1473-1479, 1998
11. von Deimling A, Louis DN, von Ammon K, et al: Evidence for a tumor suppressor gene on chromosome 19q associated with human astrocytomas, oligodendrogliomas, and mixed gliomas. Cancer Res 52:4277-4279, 1992
12. von Deimling A, Nagel J, Bender B, et al: Deletion mapping of chromosome 19 in human gliomas. Int J Cancer 57:676-680, 1994
13. von Deimling A, Bender B, Jahnke R, et al: Loci associated with malignant progression in astrocytomas: A candidate on chromosome 19q. Cancer Res 54:1397-1401, 1994
14. Reifenberger J, Reifenberger G, Liu L, et al: Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p. Am J Pathol 145:1175-1190, 1994
15. Ritland SR, Ganju V, Jenkins RB: Region-specific loss of heterozygosity on chromosome 19 is related to the morphologic type of human glioma. Genes Chrom Cancer 12:277-282, 1995
16. Kraus JA, Koopman J, Kaskel P, et al: Shared allelic losses on chromosomes 1p and 19q suggest a common origin of oligodendroglioma and oligoastrocytoma. J Neuropathol Exp Neurol 54:91-95, 1995
17. Bello MJ, Leone E, Vaquer J, et al: Allelic loss at 1p and 19q frequently occurs in association and may represent early oncogenic events in oligodendroglial tumors. Int J Cancer 64:207-210, 1995
18. Dinapoli RP, Brown LD, Arusell RM, et al: Phase III comparative evaluation of PCNU and carmustine combined with radiation therapy for high-grade glioma. J Clin Oncol 11:1316-1321, 1993
19. Rosenberg JE, Lisle DK, Burwick JA, et al: Refined deletion mapping of the chromosome 19q glioma tumor suppressor gene to the D19S412-STD interval. Oncogene 13:2483-2485, 1996
20. Smith JS, Jenkins RB: Loss of heterozygosity mapping of the chromosome 19q- arm in human gliomas. FASEB Lett 11:3131, 1997 (abstr 451)
21. Jenkins RB, Qian J, Lee HK, et al: A molecular cytogenetic analysis of 7q31 in prostate cancer. Cancer Res 58:759-766, 1998
22. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
23. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163-170, 1966
24. Cox DR: Regression models and life tables. J R Stat Soc B 34:187-220, 1972
25. Perry A, Nobori T, Ru N, et al: Detection of p16 gene deletions in gliomas: A comparison of fluorescence in situ hybridization (FISH) versus quantitative PCR. J Neuropathol Exp Neurol 56:999-1008, 1997
26. Louis DN, Gusella JF: A tiger behind many doors: Multiple genetic pathways to malignant glioma. Trends Genet 11:412-415, 1995
27. Kim DH, Mohapatra G, Bollen A, et al: Chromosomal abnormalities in glioblastoma multiforme tumors and glioma cell lines detected by comparative genomic hybridization. Int J Cancer 60:812-819, 1995
28. Ransom DT, Ritland SR, Moertel CA, et al: Correlation of cytogenetic analysis and loss of heterozygosity studies in human diffuse astrocytomas and mixed oligoastrocytomas. Genes Chrom Cancer 5:357-374, 1992
29. Perry A, Anderl K, Borell TJ, et al: Detection of p16, RB, CDK4, and p53 gene deletion/amplification by fluorescence in situ hybridization (FISH) in 96 gliomas. Am J Clin Pathol 112:801-809, 1999
30. Maintz D, Fiedler K, Koopman J, et al: Molecular genetic evidence for subtypes of oligoastrocytomas. J Neuropathol Exp Neurol 56:1098-1104, 1997
31. Schwab M, Praml C, Amler LC: Genomic instability in 1p and human malignancies. Genes Chrom Cancer 16:211-229, 1996
32. Atkin NB: Chromosome 1 aberrations in cancer. Cancer Genet Cytogenet 21:279-285, 1986
33. Heim S, Mitelman F: Cancer Cytogenetics. New York, NY, Alan R. Liss Inc, 1987
34. Oláh E, Balogh E, Kovács I, et al: Abnormalities of chromosome 1 in relation to human malignant diseases. Cancer Genet Cytogenet 43:179-194, 1989
35. Kaghad M, Bonnet H, Yang A, et al: Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell 90:809-819, 1997
36. Mai M, Huang H, Reed C, et al: Genomic organization and mutation analysis of p73 in oligodendrogliomas with chromosome 1 p-arm deletions. Genomics 51:359-363, 1998
37. Seizinger B, Klinger HP, Junien C, et al: Report of the committee on chromosome and gene loss in human neoplasia. Cytogenet Cell Genet 58:1080-1096, 1991
38. Yong WH, Ueki K, Chou D, et al: Cloning of a highly conserved human protein serine-threonine phosphatase gene from the glioma candidate region on chromosome 19q13.3. Genomics 29:533-536, 1995
39. Chou D, Miyashita T, Mohrenweiser HW, et al: The BAX gene maps to the glioma candidate region at 19q13.3, but is not altered in human gliomas. Cancer Genet Cytogenet 88:136-140, 1996
40. Peters N, Smith JS, Tachibana I, et al: The human glia maturation factor-gamma (hGMF-γ) gene: Genomic structure and mutation analysis in gliomas with chromosome 19q loss. Neurogenetics 2:163-166, 1999